Explore

Rapid Read Rapid Read
FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

The U.S. Food and Drug Administration (FDA) has released a white paper titled “Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations.” This document outlines important considerations for leveraging digital health technologies (DHTs) to collect data in clinical trials. The FDA emphasizes that DHTs, particularly those enhanced by artificial intelligence, can continuously capture health information in real-time and within a person's daily life, expanding beyond traditional periodic clinic visits. This initiative aligns with the FDA’s mission to protect and advance public health by supporting innovation in medical product development. The white paper aims to guide the development and use of digitally derived measures (DDMs) as outcomes in clinical investigations, advancing one of the FDA’s priorities under Public Health Pillar 1: strengthening the use of emerging technologies.
Rapid Read Rapid Read
Tolerance Bio Licenses IL-7 Therapy from NeoImmuneTech to Advance Healthspan and Immune Resilience Programs

Tolerance Bio Licenses IL-7 Therapy from NeoImmuneTech to Advance Healthspan and Immune Resilience Programs

Tolerance Bio, a biotechnology company focused on preserving and regenerating thymic function, has secured an exclusive license agreement with NeoImmuneTech (NIT) for efineptakin alfa, a clinical-stage long-acting Interleukin-7 (IL-7) fusion protein. This agreement grants Tolerance Bio development and commercialization rights for certain thymus-related indications in the Americas and Europe. Efineptakin alfa, also known as NT-I7, is designed to extend the half-life and sustain IL-7 activity, which stimulates thymic function and T-cell differentiation. The company plans to advance efineptakin alfa into Phase 2 clinical trials, with initial evaluations targeting HIV immunological non-response, a model for accelerated immune aging. This move marks Tolerance Bio's transition into a clinical-stage biotechnology company, expanding its pipeline of therapies aimed at thymus biology, including biologics, thymus-targeted mRNA, and thymus cell therapies. The IL-7 therapeutic class has a proven track record of boostin...
Rapid Read Rapid Read
Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

The development of new cancer drugs is an arduous and expensive process, often exceeding a billion US dollars and taking nearly a decade, with a high rate of failure. A primary reason for these failures is recruitment issues in clinical trials, a problem exacerbated by the increasing fragmentation of cancer entities into molecularly-defined subgroups in the era of precision oncology. This leads to multiple trials competing for a shrinking pool of eligible patients. Generative artificial intelligence (AI) is emerging as a potential solution by creating synthetic data that is indistinguishable from real data. This AI can generate medical images, text from electronic health records, and tabular data, including laboratory parameters, genetics, and outcomes. Unlike digital twins, which are digital replicas of individual patients, synthetic data statistically mimics feature distributions to create new samples without being exact copies of original training data. This technology aims to address the challenges of ...
Rapid Read Rapid Read
New Discovery Offers Hope for Combating Drug-Resistant Fungal Infections Amid Shortage

New Discovery Offers Hope for Combating Drug-Resistant Fungal Infections Amid Shortage

Researchers from the Monash Warwick Alliance have identified gladiolin, a bacterial antibiotic, as a potential new tool in the fight against life-threatening fungal infections. This discovery is particularly significant given the global shortage of effective antifungal drugs and the rise of drug-resistant pathogens, especially those forming on medical devices. Gladiolin has been found to disarm *Candida albicans*, a common cause of severe fungal infections, by switching it from its tissue-damaging 'hyphae' form back to a less harmful 'yeast' state. The molecule achieves this by altering the fungus's metabolism, causing it to consume glucose more rapidly, thereby hindering its invasive growth. This research, published in *Current Biology*, suggests that gladiolin could enhance the efficacy of existing antifungal treatments, potentially allowing for lower, less toxic dosages. Fungal infections are a major global health concern, responsible for an estimated two million deaths annually, with limited and often ...
Rapid Read Rapid Read
Merck and Moderna Announce Positive Late-Stage Trial Results for mRNA Cancer Vaccine in Melanoma

Merck and Moderna Announce Positive Late-Stage Trial Results for mRNA Cancer Vaccine in Melanoma

Merck and Moderna have announced successful late-stage clinical trial results for their personalized mRNA cancer vaccine, intismeran, when combined with Merck’s Keytruda. The trial focused on adjuvant melanoma, where patients had their disease surgically removed. The drugmakers reported that the combination treatment significantly slowed the recurrence of melanoma and its spread to other parts of the body. This marks the first randomized Phase 3 clinical trial to definitively prove the benefit of neoantigen vaccines in cancer treatment. While detailed data has not yet been released, the preliminary findings suggest a promising new approach in oncology. The vaccine utilizes mRNA technology, which has also been instrumental in developing traditional vaccines and therapeutics.
Rapid Read Rapid Read
NIH-Funded Study Reveals Brain Organoids Exhibit Lifelike Developmental Clock, Enabling Long-Term Neurodevelopmental Research

NIH-Funded Study Reveals Brain Organoids Exhibit Lifelike Developmental Clock, Enabling Long-Term Neurodevelopmental Research

A scientific team funded by the National Institutes of Health (NIH) has achieved a significant breakthrough in brain organoid research, demonstrating that these 3D cell culture models of human brain tissue can exhibit features of later-stage brain development and maintain viability for nearly six years. This extended longevity and lifelike maturation were previously unattainable, limiting the scope of research into neurodevelopmental disorders. The study, led by Paola Arlotta, Ph.D., at Harvard University, built upon previous work that addressed batch-to-batch variability in organoid production. Researchers tracked gene expression, biological age, and cellular structure, observing the emergence and maturation of neurons and glial cells at a pace consistent with natural human brain development. The organoids also demonstrated functional maturity, establishing connections and firing electrical signals for at least two years, supported by a specialized fluid environment.
Rapid Read Rapid Read
Study Identifies Elevated FGF2 and Inflammatory Markers in ALS Patients, Suggesting New Diagnostic Avenues

Study Identifies Elevated FGF2 and Inflammatory Markers in ALS Patients, Suggesting New Diagnostic Avenues

A recent exploratory study has found significantly elevated levels of fibroblast growth factor 2 (FGF2) and peripheral blood inflammatory indicators (PBIIs) in patients with Amyotrophic Lateral Sclerosis (ALS) compared to healthy individuals. The research, conducted by scientists at the First Affiliated Hospital of Wenzhou Medical University, aimed to understand the interplay between neurotrophic factors and inflammatory responses in ALS. The study observed strong correlations between FGF2, PBIIs, clinical staging, and disease progression rates. Specifically, PBIIs, particularly the systemic inflammatory response index (SIRI), were significantly associated with disease severity and early progression. The ratio of serum FGF2 to derived neutrophil-to-lymphocyte ratio (dNLR) also showed potential as an auxiliary biomarker for later-stage disease. These findings suggest a coordinated dysregulation of neurotrophic support and systemic inflammation in ALS pathophysiology, providing new insights into the molecula...
Trendline Trendline
Regeneron Terminates Eye Disease Study Due to Unfavorable Risk/Benefit Profile of Investigational Antibody

Regeneron Terminates Eye Disease Study Due to Unfavorable Risk/Benefit Profile of Investigational Antibody

Regeneron Terminates Eye Disease Study Due to Unfavorable Risk/Benefit Profile of Investigational Antibody
Rapid Read Rapid Read
New Research Explores Noninvasive Nasal Drug Delivery to the Brain

New Research Explores Noninvasive Nasal Drug Delivery to the Brain

A recent study published in Experimental & Molecular Medicine has analyzed various scientific breakthroughs concerning the noninvasive delivery of drugs to the brain via nasal routes. The research highlights the significant challenge posed by the blood-brain barrier (BBB), a protective layer that prevents harmful substances from entering the brain but also obstructs therapeutic drugs. While the nose offers a fast, needle-free pathway that bypasses the BBB and avoids initial drug breakdown in the liver, its efficiency in clearing foreign substances limits drug absorption time. The study identifies three advanced delivery strategies that could protect drug molecules during their journey through the nose: nanoparticles, extracellular vesicles, and living systems like genetically engineered cells, viruses, and bacteria. These systems aim to overcome the anatomical limitations of human nasal passages, which have a much smaller olfactory epithelium compared to rodents, making direct drug delivery less effective....
Trendline Trendline
AstraZeneca Halts Phase 3 Lung Cancer Trial for Volrustomig Due to Insufficient Efficacy

AstraZeneca Halts Phase 3 Lung Cancer Trial for Volrustomig Due to Insufficient Efficacy

AstraZeneca Halts Phase 3 Lung Cancer Trial for Volrustomig Due to Insufficient Efficacy
Rapid Read Rapid Read
Longeveron Secures $1 Million XPRIZE Healthspan Milestone Award for Stem Cell Therapy

Longeveron Secures $1 Million XPRIZE Healthspan Milestone Award for Stem Cell Therapy

Longeveron, a Miami-based regenerative medicine company, has been awarded a $1 million Milestone 2 award in the $101 million XPRIZE Healthspan competition. This recognition stems from their clinical trial data demonstrating that their lead candidate, laromestrocel, an allogeneic mesenchymal stem cell (MSC) therapy, increased the six-minute walk distance in patients with aging-related frailty. Laromestrocel is derived from the bone marrow of young, healthy adult donors and is designed for broad, one-time intervention, working through anti-inflammatory, pro-vascular, and pro-regenerative effects. The XPRIZE Healthspan competition aims to develop and test therapies that can restore muscle, cognition, and immune function lost to aging by at least ten years within a year or less of treatment. Longeveron was one of ten teams selected from over 600 international entries to advance to this milestone.
Rapid Read Rapid Read
Shorter Antibiotic Courses Found Effective, Challenging Long-Standing Medical Advice

Shorter Antibiotic Courses Found Effective, Challenging Long-Standing Medical Advice

A review of over 120 randomized controlled trials has revealed that shorter courses of antibiotics for common infections can be as effective and safer than longer courses, while also being no more likely to promote antibiotic resistance. This finding challenges the long-held medical advice, prevalent since the 1940s, that patients must always complete their full course of antibiotics. Experts, including population health researcher Alistair Thorpe of the University of Utah, indicate that unnecessary prolonged exposure to antibiotics might actually contribute to the problem of antibiotic resistance. The study, published in Open Forum Infectious Diseases, surveyed 1,475 U.S. respondents, finding that a majority (892) preferred longer courses, often due to prior medical advice and a belief that longer treatments are inherently better. However, many respondents (58.4 percent) expressed comfort with the idea of stopping antibiotics when feeling better, if advised by their clinician.